Empowered Funds
TCRX icon

Empowered Funds’s TScan Therapeutics TCRX Stock Holding History

Empowered Funds’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$21.8K Buy
+69,207
New +$47.8K ﹤0.01% 2509

Other funds holding TCRX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $741K AUM 2.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Empowered Funds's TCRX Position: Q3 2026 in Review

Empowered Funds opened a new position in TScan Therapeutics (TCRX) in Q3 2026: 69,207 shares worth $21.8K. The stake represents ﹤0.01% of the portfolio and ranks #2509 among its holdings.

33 funds tracked by Wall St. Rank hold TCRX as of Q3 2026.

  • Empowered Funds held 69,207 shares of TScan Therapeutics worth $21.8K as of Q3 2026.
  • TScan Therapeutics was a new Empowered Funds position in Q3 2026.
  • TScan Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2509 holding.
  • 33 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.